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THERAPEUTICS
Statins for the primary prevention of cardiovascular
disease
Shah Ebrahim professor of public health and policy 1, Fiona C Taylor managing editor, Cochrane
Heart Group 1, Peter Brindle general practitioner 2
1Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Health, London WC1E 7HT, UK; 2Avon Primary
Care Research Collaborative, Bristol Clinical Commissioning Group, Bristol BS1 3NX, UK
This is one of a series of occasional articles on therapeutics for common
or serious conditions, covering new drugs and old drugs with important
new indications or concerns. The series advisers are Robin Ferner,
honorary professor of clinical pharmacology, University of Birmingham
and Birmingham City Hospital, and Albert Ferro, professor of
cardiovascular clinical pharmacology, King’s College London. To suggest
a topic for this series, please email us at practice@bmj.com.
A 55 year old former financial services manager attended a
cardiovascular risk check, which showed he had a 15% risk of
suffering a major cardiovascular event in the next 10 years.1He
asks his general practitioner whether he needs a statin given his
risk. His risk factors are being overweight; moderate smoker;
blood pressure 150/90 mm Hg; and serum total cholesterol
concentration 5.5 mmol/L, high density lipoprotein cholesterol
1.2 mmol/L, low density lipoprotein cholesterol 3.5 mmol/L,
triglycerides 1.7 mmol/L.
What are statins?
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, involved in cholesterol biosynthesis.
Low density lipoprotein (LDL) cholesterol concentration is
lowered by reducing its production in the liver and increasing
removal from the circulation.2 Lowering blood levels of LDL
cholesterol, a major risk factor for cardiovascular disease,
reduces the chances of having cardiovascular disease. Statins
also have anti-inflammatory effects, improve endothelial
function, and reduce thrombus formation, but these effects may
not be independent of cholesterol lowering or reduce
cardiovascular disease risk.3 Expert committees promote their
use on a global scale,4-7 and statin prescribing and expenditure
have risen rapidly. In England, prescriptions for statins rose
fivefold from 2001 to 2011 to £61m a year (£544 average annual
cost per person).8
How well do they work?
Statins are indicated for secondary prevention of cardiovascular
disease. The Cholesterol Treatment Trialists Collaboration
reviewed data from 27 clinical trials of statins (170 000
participants) for both primary and secondary prevention and
reported a 20% relative risk reduction per 1 mmol/L reduction
in LDL cholesterol concentration for major vascular events.
These beneficial effects were seen in both men and women, at
ages from <60 to >70 years, in people with and without
cardiovascular disease, in those at high and low cardiovascular
disease risk, in diabetics, and in those with average levels of
blood cholesterol.9
ACochrane systematic review of statins for primary prevention
of cardiovascular disease included 18 trials (56 934 participants,
most with one or more cardiovascular disease risk factor).10 It
found that statins lowered cardiovascular disease risk by 27%
(table⇓). The median level of cardiovascular disease risk
observed in the control groups of the trials was equivalent to
15% over 10 years (the same as the current case). Over five
years, the number needed to treat (NNT5) to avoid one
cardiovascular event was 50. The NNT5 for people at 10%, 20%,
and 30% predicted cardiovascular event risk over 10 years were
74, 37, and 25 respectively. These compare with NNT5 values
of between 12 and 34 in secondary prevention.
How safe are they?
Use of statins by low risk patients has been criticised on the
grounds that their benefits do not outweigh their harms12 and
debated.13 14However, all cause mortality in people taking statins
with no pre-existing cardiovascular disease is reduced (table⇓),
indicating that any unintended life threatening effects are
outweighed by their beneficial impact on cardiovascular disease,
although this evidence is not strong.15 Earlier concerns about
cancer risk are unfounded.16 However, other unintended effects
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are not comprehensively reported in systematic reviews or
trials.17
Adverse events and stopping treatment because of them are
common, but occur at similar rates in treated and control groups
in clinical trials (17% and 12% respectively),10making it difficult
to ascribe these events to statins. Reports of reduced energy,
fatigue, depressed mood, and reduced quality of life show
inconsistent findings.18-20 Myositis (a ≥10-fold rise in normal
levels of creatine kinase) is caused by statins, but myalgia
(muscle pain without raised creatine kinase) is not linked with
statin use.21 In two large, well conducted, observational analyses
using national primary care datasets, the numbers needed to
harm for incident myositis associated with five years of statin
treatment were between 9022 and 250.23 Rhabdomyolysis—an
extreme form of myositis that can be serious if not detected and
treated early—may be caused by statins but is very rare.24
Myositis and other adverse effects are more common with
aggressive lowering of cholesterol levels by means of potent
statins such as rosuvastatin or higher doses of statins (such as
doubling of usual doses).25
Statins are associated with an increased risk of developing type
2 diabetes,11 26 especially at higher doses.27 Only two primary
prevention trials reported on type 2 diabetes outcomes, with a
pooled relative risk of 1.18 (95% confidence interval 1.01 to
1.39). This result is consistent with a larger meta-analysis that
included both primary and secondary prevention trials, which
found that treating 255 people for four years would cause one
case of diabetes, but this would be offset by avoiding more than
five major vascular events (table⇓).11 This increased risk of
diabetes was related to baseline fasting glucose levels among
trial participants.28
Haemorrhagic stroke was not increased by use of statins in a
meta-analysis of randomised trials (odds ratio 1.08 (95%
confidence interval 0.88 to 1.32)).29 Large observational primary
care datasets found no strong evidence that statins were
associated with an increased risk of Parkinson’s disease,
rheumatoid arthritis, venous thromboembolism, dementia,
osteoporotic fracture, or infections, and confirmed the evidence
from randomised trials of no increased risk of cancer.22 23 Other
possible adverse effects of statins (cataracts, depression, and
peripheral neuropathy) and possible benefits (on bone mineral
density, cognition, and macular degeneration) have not been
confirmed in randomised trials.20
Patients may expect not to be harmed in any way by preventive
treatment with statins, and their views of trade-offs between
benefit and possible harms will likely determine the wider use
of statins.30
How are statins taken?
The National Institute for Health and Care Excellence (NICE)
guidelines recommend that, before starting a statin, all patients
should have a comprehensive assessment of their cardiovascular
risk factors and secondary causes of dyslipidaemia considered
(see box 1).31 Patients should be advised to deal with modifiable
risk factors before starting statins. Current NICE guidance uses
a threshold of ≥20% for 10 year risk of cardiovascular disease
for using statins. People at lower cardiovascular risk may also
benefit, however,9 and the new American College of
Cardiology/American Heart Association guideline has lowered
its treatment threshold to a predicted 7.5% for 10 year
cardiovascular risk.32
What are the precautions?
General contraindications to prescribing statins include women
during pregnancy and breast-feeding, previous hypersensitivity
reactions to a statin, active liver disease, renal failure, and heavy
drinkers (50+ units a week). Both the USA and UK drug
regulatory agencies have issued safety alerts advising blood
glucose monitoring in patients at risk of developing diabetes
and taking statins.33 34 However, based on current evidence,
statins should not be avoided in patients with pre-existing
diabetes who are at high risk of cardiovascular disease.
Drug interactions
Many drugs aremetabolised by the cytochrome P450 isoenzyme
system, which also metabolises statins, and consequently
drug-drug interactions may occur.35 Patients with renal disease,
HIV infection, and organ transplants are more prone to
interactions. A wide range of drugs have been implicated in
interactions. Patients treated with these drugs should be
monitored for possible side effects, such as muscle pain and
gastrointestinal symptoms (see box 2). Patients taking
simvastatin should be advised to avoid drinking grapefruit juice.
Lower doses of statins are less likely to provoke clinically
important interactions.
How cost effective are statins?
For primary prevention of cardiovascular disease, cost per
QALY is variable depending on the level of cardiovascular
disease risk, age, and cost of statins, with NICE supporting their
use in people with predicted 10 year cardiovascular risk of
>20%.6 The costs per QALY were based on NHS costs in 2004
when most statins were still in patent. These estimates need
updating given the large reductions in their costs.
How do statins compare with other drugs
and interventions?
Statins are not the only means of reducing risk of cardiovascular
disease. People at high cardiovascular risk can reduce their risk
by making lifestyle changes (see figure⇓ and case outcome).
If a statin is not tolerated, switching to an alternative statin and
starting at a low dose may work. Fibrates (bezafibrate,
ciprofibrate, fenofibrate, gemfibrozil) lower cholesterol, but
evidence of clinical effectiveness is limited. NICE recommends
use of ezetimibe when statins are contra-indicated or not
tolerated, or in conjunction with a statin when LDL cholesterol
concentration is not controlled by optimal statin therapy.31
Combination statin and fibrate treatment may be used when
blood triglyceride levels are raised and are not controlled with
a statin alone. However, evidence of clinical benefits from
combination treatment is limited and side effects (such asmuscle
pain) are common.
Nicotinic acid, plant sterols and stanols, anion exchange resins,
and omega 3 fatty acid supplements are not recommended by
NICE for cholesterol lowering in primary prevention.
Case outcome
Stopping smoking would reduce the patient’s predicted 10 year
cardiovascular disease risk from 15% to 11%. If he takes a statin
instead and gains the typical 1 mmol/L reduction in LDL
cholesterol level, this too would reduce his predicted
cardiovascular disease risk to 11% (see figure⇓). Stopping
smoking and taking a statin would reduce this further to 9%
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Box 1: Monitoring statins in practice
Baseline measurements
Fasting total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides
Blood glucose, renal function, and liver function tests (transaminases)
Thyroid function tests to exclude hypothyroidism as a cause of dyslipidaemia
Repeated measurements
NICE considers that it is unnecessary to make repeated measures of blood lipid profiles routinely
Liver function should be measured within 3 months of starting treatment and at 12 months, but not again unless clinically indicated
Indications for creatine kinase measurements
Measure this in patients complaining of muscle symptoms (pain, tenderness or weakness)
Refer if concentration is raised ≥5 times above the upper limit of normal range
If concentration is raised <5 times above the upper limit, symptoms should be monitored carefully and creatine kinase measurement
repeated a month later. If still raised, reduce the statin dose and recheck creatine kinase a month later. If symptoms persist or creatine
kinase levels remain high, specialist advice should be sought
Creatine kinase should not be routinely monitored in asymptomatic people being treated with a statin
Box 2: Statins and interacting drugs36
Macrolide antibiotics—Erythromycin, clarithromycin, telithromycin
Azole antifungals—Itraconazole, ketoconazole, posaconazole
Protease inhibitors—Amprenavir, indinavir, nelfinavir, ritonavir, saquinavir
Immunosuppressive drugs—Ciclosporin
Fibrates—Gemfibrozil
Cardiovascular drugs—Amiodarone, verapamil, diltiazem, amlodipine, ranolazine, warfarin
Antidepressant drugs—Nefazodone
Other drugs—Sildenafil, danazol
As he is overweight and hypertensive, a programme of alcohol
reduction, increased physical activity, and attending a weight
reduction course might achieve a lower blood pressure and
would combat other cardiovascular risk factors not included in
the risk score. Adding a statin to these lifestyle measures would,
on average, almost halve his risk to 8% (assuming he does not
revert to his adverse lifestyle as the statin is now “doing the
job”) with an NNT5 of approximately 60 for cardiovascular
disease events.
His predicted 10 year cardiovascular disease risk is lower than
the NICE threshold of ≥20%; treating him with a statin would
go against current English guidance.
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Tips for patients
• You can reduce your chances of having a heart attack or stroke
• The common risk factors are smoking, high blood pressure, raised blood cholesterol (circulating fat in the bloodstream), and lack of
exercise. All of these can be improved with beneficial results
• Consider checking your own risk and seeing what effect lifestyle changes could have on reducing your risk (see http://qintervention.
org/). Decision making tools such as the Mayo Clinic’s (http://statindecisionaid.mayoclinic.org/index.php/statin/index) and the National
Prescribing Centre’s (www.npc.nhs.uk/therapeutics/cardio/cd_lipids/resources/pda_Lipids.pdf) may help you to weigh up the risks
and benefits of taking statins
• Statins lower your cholesterol level and reduce your chances of having a heart attack or stroke
• There is no evidence that statins cause cancer or dementia or increase your risk of dying from other diseases
• Statins may increase your chance of developing diabetes, particularly if you are obese, physically inactive, and have a family history
of diabetes. Even then, the benefits of taking statins outweigh the smaller risk of developing diabetes
• People with diabetes benefit from taking statins
• If you get muscle pains while taking a statin you should consult your GP, who may want to do a blood test and may reduce your statin
dose or advise taking it on alternate days
• Statins are more effective if taken in the evening on going to bed
• Grapefruit juice should be completely avoided if you are taking simvastatin as it can worsen the side effects, but this is not such a
problem with atorvastatin
• Statins have to be taken every day and for the foreseeable future – they won’t work if you don’t take them
• Some drugs must be avoided or used with caution when taking statin. Consult your GP before taking any other drugs with a statin
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Table
Table 1| Effects of statins on from trials in primary prevention6
Number needed to treat or harm
for 5 years (95% CI)
Absolute 10 year risk reduction
or increase (%)
Median control group 10
year risk (%)Relative risk (95% CI)Clinical outcome
49 (40 to 66)4.06 (3.01 to 4.97)15.050.73 (0.67 to 0.80)Combined fatal and non-fatal
cardiovascular events
155 (106 to 309)1.29 (0.65 to 1.88)5.880.78 (0.68 to 0.89)Combined fatal and non-fatal
stroke
138 (92 to 321)1.45 (0.62 to 2.18)10.40.86 ( 0.79 to 0.94)All cause mortality
Unintended effects (numbers needed to harm)
198 (105 to 889)0.98 (0.23 to 1.91)11.251.09 (1.02 to 1.17)Type 2 diabetes*
*Estimates from Satter et al.11
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Figure
Predicted cardiovascular disease risk (percent) over 10 years for given characteristics based on QRISK Intervention software1
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